news Animal model market set to grow to $24bn by 2025 2 December 2019 | By Victoria Rees (Drug Target Review) New research has found that the animal model market for disease research and therapeutic testing will exhibit strong growth.
article Taking the brakes off the immune system: modelling effects in non-clinical safety studies 2 May 2018 | By Greg Bannish - Vice President Biopharmaceutical Development Envigo This article focuses on how the immune system functions, the challenges that it presents to drug development and why there are such concerns around safety that need to be investigated in pre-clinical studies. Moreover, it covers the role of checkpoint inhibitors as an attractive target for cancer immunotherapy.
news Envigo expands R&D capabilities in non-animal technologies 17 March 2017 | By Niamh Marriott (Drug Target Review) Envigo is helping to define the non-animal technologies regulatory environment, with its scientists currently sitting on OECD expert working groups...
news Envigo collaboration with OCSiAl and Intertek results in single wall carbon nanotubes 14 October 2016 | By Niamh Louise Marriott, Digital Content Producer Over the course of six months, scientists at OCSiAl, Envigo and InterTek collaborated to conduct extensive research and testing on potentially hazardous...
news Envigo invests in non-animal assays, research and development 27 September 2016 | By Niamh Louise Marriott, Digital Content Producer One example is the development of in vitro assays to enable the testing of 100 or so compounds per month for potential endocrine disrupting effects...